A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment

BACKGROUND AND OBJECTIVES: In 10% to 20% of cases, Kawasaki disease is refractory to intravenous immunoglobulin (IVIg), an expensive medication under a national shortage. Data suggest that infliximab is a viable alternative to a second dose of IVIg, with similar efficacy and safety. We compared the...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Hosp Pediatr
Main Authors: Johnson, Scarlett Carmen, Williams, Daniel Clay, Brinton, Daniel, Chew, Marshall, Simpson, Annie, Andrews, Annie Lintzenich
Format: Artigo
Jezik:Inglês
Izdano: American Academy of Pediatrics 2021
Teme:
Brief Reports
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7769204/
https://ncbi.nlm.nih.gov/pubmed/33293266
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1542/hpeds.2020-0188
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki